# ArriVent Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arrivent-biopharma

- Industry: Biotechnology
- Headquarters: US
- Website: www.arrivent.com
- Total disclosed funding: $191M
- Latest round: Series B (Dec 16, 2022)
- Investors on record: 18

## About

Based in Pennsylvania, US, and founded in 2021, ArriVent Biopharma, Inc. operates as a company that focuses on accelerating the global development of innovative biopharmaceutical products from pharmaceutical companies and other emerging biotech hubs. Stuart Lutzker and Bing Yao co-founded the company. In March 2023, ArriVent Biopharma, Inc. raised USD 155 million in series B funding co-led by new investors General Catalyst Partners and Sofinnova Investments, with participation from other new investors AIHC Capital, Catalio Capital Management, HBM Partners, Infinitum Partners, Sequoia Capital, Shanghai Healthcare Capital, Terra Magnum Capital Partners, and Unicorn Capital Partners.

ArriVent Biopharma has a network of biotechs and big Pharma that provides the company with access to drug candidates at various development stages from biotech hubs. The company identifies potential candidates focusing on compounds validated through rigorous discovery and development processes and aims to commercialize these medicines globally for patients with a broad range of diseases, starting with oncology.

Arrivent Biopharm plans to file an investigational new drug application with the U.S. FDA to further develop furmonertinib in patients with epidermal growth factor receptor tyrosine kinase inhibitor EGFR, and potentially other solid tumors, by the end of 2021. The company also plans to expand the team with in-depth scientific and clinical development expertise and will continue to support the buildout of its portfolio of innovative medicines.

## Funding rounds

- Series B, Dec 16, 2022, $110M — OrbiMed Advisors, Hong Shan, Sofinnova Investments, General Catalyst Partners, HBM Partners, Lilly Asia Ventures, Boyu Capital, Unicorn Capital Partners, Sirona Capital, Terra Magnum Capital Partners, AIHC Capital, Catalio Capital Management, Octagon Capital Advisors, Shanghai Healthcare Capital, Infinitum Partners
- Series A, Jun 9, 2021, $81M — OrbiMed Advisors, Lilly Asia Ventures, Boyu Capital, Hillhouse Investment, Lyra Capital, Octagon Capital Investments

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A, Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series A
- Lyra Capital — Series A
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series A
- Hong Shan — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Unicorn Capital Partners (https://capitalatlas.ai/funds/unicorn-capital-partners) — Series B
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- AIHC Capital — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B
- Infinitum Partners (https://capitalatlas.ai/funds/infinitum-partners) — Series B